TransMedics Group, Inc. logo
TransMedics Group, Inc. (TMDX)
Compare

TransMedics Group, Inc. (TMDX) Price/FCF Ratio: 18.84

popular:market cap|pe ratio|revenue|price history|total return

Is TransMedics Group, Inc.’s Price/FCF ratio high or low?

TransMedics Group, Inc.'s Price/FCF ratio of 18.84 is 82% below its 1-year average of 104.61, near the low end of its 1-year range (14.84–309.59).

P/E Ratio|FCF Growth|Operating Margin|All Metrics

TMDX Price/FCF Ratio Chart

TMDX Price/FCF Ratio
18.84-53.93% 6M
Zoom

TMDX Price/FCF Ratio Metrics

PRICE/FCF RATIO

18.84

PRICE/FCF RATIO AVG TTM

N/A

PRICE/FCF RATIO AVG 3Y

N/A

PRICE/FCF RATIO AVG 5Y

N/A

PRICE/FCF RATIO AVG 10Y

N/A

PRICE/FCF RATIO AVG 15Y

N/A

PRICE/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

TMDX Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
TransMedics Group, Inc. (TMDX)$2.72B18.84N/AN/AN/A
DENTSPLY SIRONA Inc. (XRAY)vs ›$2.07B19.8622.0121.5420.27
23andMe Holding Co. (ME)vs ›$15.31MN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. (BIO)vs ›$7.64B21.3222.3538.8247.51
Hims & Hers Health, Inc. (HIMS)vs ›$7.91B106.8078.2371.0671.06
Tempus AI, Inc. (TEM)vs ›$8.87BN/AN/AN/AN/A
Charles River Laboratories International, Inc. (CRL)vs ›$8.91B23.1416.4322.6928.28
Baxter International Inc. (BAX)vs ›$10.27B14.3538.5130.9330.24
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B17.8617.1329.6417.62
Revvity, Inc. (RVTY)vs ›$11.16B22.6521.97204.66127.14

Free Cash Flow Valuation

P/FCF Ratio

18.8

FCF Yield

5.31%

TransMedics Group, Inc. Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

TransMedics Group, Inc. Price/FCF Ratio FAQ

What is the Price/FCF ratio for TransMedics Group, Inc. (TMDX)?
The Price/FCF ratio for TMDX stock is 18.84.
Is TransMedics Group, Inc.'s Price/FCF ratio high or low?
TransMedics Group, Inc.'s Price/FCF ratio of 18.84 is 82% below its 1-year average of 104.61, near the low end of its 1-year range (14.84–309.59).

TransMedics Group, Inc. Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1818.84
2026-06-1717.51
2026-06-1618.13
2026-06-1518.05
2026-06-1217.43
2026-06-1117.60
2026-06-1017.88
2026-06-0917.76
2026-06-0817.01
2026-06-0516.60
2026-06-0417.07
2026-06-0316.66
2026-06-0216.37
2026-06-0116.15
2026-05-2916.07
2026-05-2816.22
2026-05-2716.77
2026-05-2616.85
2026-05-2216.49
2026-05-2116.46
2026-05-2016.26
2026-05-1915.81
2026-05-1816.34
2026-05-1515.11
2026-05-1414.84
2026-05-1315.35
2026-05-1215.29
2026-05-1115.38
2026-05-0816.22
2026-05-0717.43
2026-05-0617.44
2026-05-0522.70
2026-05-0429.74
2026-05-0130.64
2026-04-3030.88
2026-04-2930.20
2026-04-2831.02
2026-04-2733.12
2026-04-2433.99
2026-04-2334.68
2026-04-2235.13
2026-04-2133.37
2026-04-2034.66
2026-04-1735.50
2026-04-1633.43
2026-04-1535.57
2026-04-1435.44
2026-04-1334.73
2026-04-1034.93
2026-04-0933.46
2026-04-0833.50
2026-04-0732.88
2026-04-0632.11
2026-04-0230.85
2026-04-0130.76
2026-03-3130.46
2026-03-3028.89
2026-03-2730.35
2026-03-2631.31
2026-03-2532.21
2026-03-2433.37
2026-03-2334.34
2026-03-2034.90
2026-03-1934.84
2026-03-1834.68
2026-03-1738.21
2026-03-1638.20
2026-03-1337.83
2026-03-1237.17
2026-03-1139.51
2026-03-1040.09
2026-03-0941.29
2026-03-0639.71
2026-03-0542.91
2026-03-0445.24
2026-03-0345.34
2026-03-0245.04
2026-02-2744.50
2026-02-2641.23
2026-02-2540.40
2026-02-2442.21
2026-02-2345.48
2026-02-2045.34
2026-02-1944.88
2026-02-1845.76
2026-02-1745.20
2026-02-1343.85
2026-02-1243.41
2026-02-1145.02
2026-02-1047.04
2026-02-0946.05
2026-02-0645.62
2026-02-0543.77
2026-02-0444.03
2026-02-0345.84
2026-02-0245.25
2026-01-3045.25
2026-01-2946.94
2026-01-2847.62
2026-01-2746.77
2026-01-2647.06
2026-01-2345.70
2026-01-2246.64
2026-01-2145.19
2026-01-2047.94
2026-01-1648.42
2026-01-1548.53
2026-01-1447.95
2026-01-1348.20
2026-01-1245.48
2026-01-0946.29
2026-01-0846.46
2026-01-0746.36
2026-01-0644.81
2026-01-0542.65
2026-01-0241.44
2025-12-3141.09
2025-12-3041.18
2025-12-2941.56
2025-12-2641.95
2025-12-2442.89
2025-12-2343.30
2025-12-2243.69
2025-12-1943.12
2025-12-1840.89
2025-12-1741.18
2025-12-1642.23
2025-12-1541.59
2025-12-1242.82
2025-12-1143.10
2025-12-1044.32
2025-12-0945.53
2025-12-0846.14
2025-12-0546.11
2025-12-0446.82
2025-12-0347.32
2025-12-0247.88
2025-12-0150.80
2025-11-2849.42
2025-11-2649.23
2025-11-2549.31
2025-11-2447.36
2025-11-2144.22
2025-11-2041.82
2025-11-1945.08
2025-11-1839.54
2025-11-1738.30
2025-11-1438.84
2025-11-1339.03
2025-11-1240.25
2025-11-1141.25
2025-11-1041.34
2025-11-0740.25
2025-11-0642.21
2025-11-0542.04
2025-11-0441.28
2025-11-0342.12
2025-10-3144.43
2025-10-3045.86
2025-10-2945.37
2025-10-28303.19
2025-10-27309.59
2025-10-24305.08
2025-10-23301.32
2025-10-22279.42
2025-10-21280.79
2025-10-20280.26
2025-10-17274.95
2025-10-16270.39
2025-10-15263.22
2025-10-14259.99
2025-10-13261.11
2025-10-10250.78
2025-10-09264.08
2025-10-08275.96
2025-10-07269.22
2025-10-06266.30
2025-10-03270.42
2025-10-02271.30
2025-10-01268.55
2025-09-30262.26
2025-09-29263.29
2025-09-26266.16
2025-09-25266.23
2025-09-24274.48
2025-09-23281.73
2025-09-22292.53
2025-09-19285.84
2025-09-18283.06
2025-09-17280.05
2025-09-16278.50
2025-09-15267.14
2025-09-12267.80
2025-09-11273.46
2025-09-10251.95
2025-09-09253.10
2025-09-08246.79
2025-09-05243.12
2025-09-04243.21
2025-09-03249.96
2025-09-02260.74
2025-08-29268.71
2025-08-28272.85
2025-08-27274.37
2025-08-26269.22
2025-08-25268.73
2025-08-22280.14
2025-08-21277.71
2025-08-20284.89
2025-08-19286.75
2025-08-18293.70
2025-08-15298.14
2025-08-14303.26
2025-08-13308.63
2025-08-12306.51
2025-08-11297.46
2025-08-08267.63
2025-08-07271.26
2025-08-06277.69
2025-08-05293.91
2025-08-04300.36
2025-08-01281.78
2025-07-31278.08
2025-07-30251.74

Related Metrics

P/E RatioFCF GrowthOperating MarginAll Metrics

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA
728 employees
www.transmedics.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Waleed H. Hassanein
View full financials